Vaibhav is currently VP Research and Therapeutic Area IT, Janssen: Pharmaceutical Companies of Johnson & Johnson. The Neuroscience Therapeutic Area at Janssen is pioneering a more personalized and holistic approach to therapeutic intervention that goes ‘beyond the pill’, to offer data-driven and science-based ‘integrated solutions’ for preventing, diagnosing, treating, and monitoring CNS diseases. Vaibhav’s work is currently focused on utilizing state-of-the-art informatics methods and digital technologies for developing markers for early diagnosis, disease progression, drug response and treatment monitoring in Alzheimer’s and Mood; and to develop novel ‘point-of-need’ tools and technologies for management of adherence and prediction of relapse in patients with Schizophrenia.
Vaibhav joined Johnson and Johnson from Eli Lilly and Co., where he headed the Discovery and Biomedical Infomatics group to enable Lilly’s translational, biomarker, and tailored therapeutics strategies. Prior to Lilly, Vaibhav held multiple leadership roles in various small to mid-size biotech companies such as Celera Genomics, CuraGen Corporation and Vertex Pharmaceuticals during which time he participated in multiple landmark ‘Big Biology’ projects, including sequencing, assembly and analysis of the human genome (Human Genome Project) and elucidation of the first complete protein-protein interaction map of a whole organism.
Vaibhav obtained his PhD from Yale University jointly from the Departments of Chemistry, and Molecular Biophysics & Biochemistry in 1998, and an Executive MBA from Kellogg School of Management, Northwestern University in 2009.